Atossa Therapeutics, Inc. (ATOS) NASDAQ
5.28
-0.21(-3.83%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
5.28
-0.21(-3.83%)
Currency In USD
Address
107 Spring Street
Seattle, WA 98104
United States of America (the)
Phone
206 588 0256
Sector
Healthcare
Industry
Biotechnology
Employees
15
First IPO Date
November 08, 2012
| Name | Title | Pay | Year Born |
| Steven C. Quay FCAP | Chairman, Chief Executive Officer & President | 1.02M | 1951 |
| Mark Daniel | Chief Financial Officer | 349,342 | 1977 |
| Richard Graydon | Interim Chief Medical Officer | 0 | N/A |
| Delly Behen | Senior Vice President of Business Operations | 0 | N/A |
| Janet Rose Rea MSPH | Senior Vice President of Research & Development | 0 | N/A |
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.